New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
10:47 EDTINCYIncyte announces results from RESPONSE trial evaluating ruxolitinib
Incyte announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera. Ruxolitinib, compared to best available therapy (BAT), significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with uncontrolled PV. Findings from the RESPONSE study are being presented in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. At a median follow-up of 81 weeks, 85% of patients in the ruxolitinib arm were still receiving treatment. Because most patients in the BAT group crossed over to receive ruxolitinib therapy at week 32, adverse events were evaluated at this time when exposure between groups was similar. The most common non-hematologic adverse events of any grade in the ruxolitinib group compared to the BAT group were headache, diarrhea, fatigue and pruritus. The company said, “One out of four patients with polycythemia vera remain uncontrolled, face a profound symptom burden and are at greater risk of cardiovascular complications such as stroke and heart attack. These Phase III data give us confidence that ruxolitinib has the potential to become an important new treatment option for patients with uncontrolled PV who are no longer responding to or are intolerant of hydroxyurea.”
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
07:31 EDTINCYIncyte to present new data on immuno-oncology portfolio at SITC
Subscribe for More Information
October 1, 2015
07:31 EDTINCYLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:30 EDTINCYIncyte to join Nasdaq-100 Index beginning Oct. 7, to replace Altera
Nasdaq yesterday announced that Incyte Corporation (INCY), will become a component of the NASDAQ-100 Index and the NASDAQ-100 Equal Weighted Index prior to market open on Wednesday, October 7, 2015. Incyte Corporation will replace Altera Corporation (ALTR). Incyte Corporation is headquartered in Palo Alto, California, and has a market capitalization of approximately $19B.
September 29, 2015
06:47 EDTINCYEli Lilly and Incyte's baricitinib Phase 3 study met primary objective
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use